Guided Therapeutics, Inc Reports Unaudited Consolidated Results for the First Quarter Ended March 31, 2014; Reaffirms Earnings Guidance for 2014
Guided Therapeutics Inc. reported unaudited consolidated results for the first quarter ended March 31, 2014. Revenue and other income for the first quarter ended March 31, 2014 was approximately $141,000, including approximately $122,000 in sales of LuViva(R) devices and disposables, NIH grants totaling approximately $13,000, as well as other income from royalties of approximately $5,000. The net loss attributable to common stockholders for the first quarter of 2014 was approximately $1.6 million, or $0.02 per basic and diluted share, compared to approximately $1.8 million, or $0.03 per basic and diluted share, in the comparable quarter of 2013. Operating loss was $2,079,000 against $1,875,000 a year ago.
The company believes it is on track to report product sales of $1 million to $3 million for 2014, in line with previous revenue guidance.